Posted by Michael Wonder on 24 Nov 2025
Swiss medical authority approves PharmaMar’s Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) combination as first-line maintenance therapy for extensive-stage small cell lung cancer
24 November 2025 - This is the first approval in Europe for lurbinectedin in this indication.
PharmaMar has announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) as a maintenance treatment for adults with extensive-stage small cell lung cancer.
